On October 6, 2023, the United States Drug Enforcement Administration (DEA) announced that the telehealth flexibility waiver, which allows healthcare providers to prescribe controlled substances via telemedicine without an in-person patient visit, would be extended through December 31, 2024.

In early 2023, the Senate Business, Professions and Economic Development Committee and the Assembly Committee on Business and Professions began their extensive sunset review oversight of eight regulatory entities, among them the Medical Board of California (MBC).

Effective June 27, 2023, any DEA-registered practitioner must complete eight (8) hours of training on the treatment and management of patients with opioid or other substance use disorders.

Consistent with the Biden Administration's timeline to end the COVID-19 national and public health emergencies on May 11, 2023, the U.S. Department of Health and Human Services (HHS) informed states to expect the Public Health Emergency (PHE) and certain associated flexibilities to end on the same date.